The Silverstein Foundation In the News
The Silverstein Foundation has been featured in national and international publications and broadcast media. Explore the links below to see and hear what others are saying about the Foundation and our Founder’s story.
News articles & blog posts
The Silverstein Foundation and Q-State Biosciences Launch Chamishi Therapeutics
NEW YORK and CAMBRIDGE, Mass., Sept 26, 2019 (GLOBE NEWSWIRE) – The Silverstein Foundation for Parkinson’s with GBA and Q-State Biosciences today announced the formation and launch of Chamishi Therapeutics, a drug discovery and development company focused on...
Prevail Therapeutics Announces Pricing of Initial Public Offering
NEW YORK--(BUSINESS WIRE)--Jun. 19, 2019-- Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the...
Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001
NEW YORK--(BUSINESS WIRE)--Jun 4, 2019-- Prevail Therapeutics Inc. (Prevail), a gene therapy company developing AAV-based gene therapies for patients with neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted the...
The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson’s with GBA Grant Nearly $3 Million to Studies into Disease’s Most Common Known Genetic Contributor
NEW YORK (February 20, 2019) - The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA announce nearly $3 million in grants to studies investigating glucocerebrosidase beta acid (GBA). Mutations in the GBA...
January, 2019: Founder Jonathan Silverstein Featured in Denison Magazine
Jonathan Silverstein ’89 has made a career out of investing in potential breakthrough cures. Now he needs to find one for himself.
October, 2018: Second Scientific Advisory Board Meeting Gathers Global Thought Leaders
New York, NY - Our Scientific Advisory Board, along with many invited guests from around the globe, gathered on October 26th, 2018 to brainstorm and vet dozens of novel ideas and proposals.
Silverstein Foundation founder Jonathan Silverstein named to Forbes Midas List of Top 100 VC’s in the world for 7th consecutive year.
March, 2018: The Silverstein Foundation and MJFF Announce Availability of Research Funding
The Silverstein Foundation for Parkinson’s with GBA and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Jointly Announce Availability of $3.5 Million in Fall 2018 Research Funding to Expand Understanding of the GBA gene in Parkinson’s Disease New York...
Year ONE: A review of accomplishments
Our First Year in Review - Announcing the launch of our NEW website This month marks the first anniversary of the launch of The Silverstein Foundation for Parkinson's with GBA. We are humbled by the outpouring of support that we have received from far and wide....
Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with Parkinson’s and Other Neurodegenerative Diseases
New York, NY – March 8, 2018 – Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, today announced a $75 million Series A financing. Investors in the round...
Video
CNBC: Investing in a cure
August, 2017—Wall Street investor Jonathan Silverstein has spent a career finding and funding biotech firms working on cures for rare diseases. But after learning in February he has Parkinson’s Disease, the diagnosis set him and his wife on a path to create a different kind of startup, a foundation to work towards a cure.
CNBC: Venture capitalist wages war against Parkinson’s, searches for miracle after his own diagnosis
August, 2017—It’s been less than a year since Jonathan Silverstein, a venture capitalist at health-care fund OrbiMed, received the diagnosis that changed everything.